API Holdings Limited has successfully completed the amalgamation of Docon Technologies Private Limited, which resulted in API Holdings acquiring 8,12,00,000 equity shares in Thyrocare Technologies Limited. This represents 51.02% of Thyrocare’s paid-up share capital. The National Company Law Tribunal sanctioned the scheme on August 31, 2026, making the amalgamation effective from September 03, 2026.
API Holdings Completes Thyrocare Amalgamation
API Holdings Limited announced the effective date of its amalgamation scheme with Docon Technologies Private Limited. The scheme, sanctioned by the Hon’ble National Company Law Tribunal (NCLT), Mumbai Bench, on August 31, 2026, became effective on September 03, 2026. This amalgamation marks a significant shift in the shareholding structure of Thyrocare Technologies Limited.
Significant Share Transfer
As a consequence of the scheme becoming operative, Docon Technologies was amalgamated with API Holdings. All assets, liabilities, undertakings, rights, and obligations of Docon were transferred to API. Critically, Docon’s entire shareholding in Thyrocare Technologies, comprising 8,12,00,000 equity shares, representing 51.02% of the company’s paid-up share capital, has now been transferred and vested in API Holdings. This transaction significantly alters the control and ownership landscape of Thyrocare.
No Change for Other Promoters
It is noteworthy that the aggregate shareholding of the Promoter and Promoter Group of Thyrocare Technologies has remained unchanged as a result of this specific amalgamation.
Regulatory Disclosure
This disclosure is made pursuant to Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The necessary disclosures in the prescribed format have been provided.
Source: BSE
